Navigation Links
BioMS Medical announces second quarter 2009 results
Date:7/17/2009

31, 2008. As at June 30, 2009, the Company had working capital of $59.8 million as compared to $81.3 million at December 31, 2008. Management estimates that the current working capital is sufficient for the Company to meet its obligations in respect of the currently initiated clinical trials.

As at June 30, 2009 there were 91,008,923 Class "A" common shares of the Company issued and outstanding.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for Secondary Progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company exclusive worldwide rights to dirucotide in exchange for an $87 million upfront payment, milestone payments and escalating royalties on sales. For further information please visit our website at http://www.biomsmedical.com

This press release may contain forward-looking statements, which reflect the Corporation's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other ri
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioMS Medical to present at the 2009 Symposium for the Canadian Society for Pharmaceutical Sciences
2. BioMS Medical to participate in panel session at Bio International Convention 2009
3. BioMS Medical Announces First quarter 2009 results
4. BioMS Medical to present at Alberta Economic Forum in Geneva
5. BioMS Medical to present at BioFinance 2009
6. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
7. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
8. BioMS Medical Announces 2008 Year End Results
9. BioMS Medical warrant extension
10. BioMS Medical to present at BIO CEO and Investor Conference
11. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... July 28, 2014 Proove Biosciences ... will be exhibiting data and research conducted through their ... Spine Intervention Society’s (ISIS) 22nd Annual Scientific Meeting. ... the Hyatt Regency, in Orlando, Florida. , ... clinical competence of physicians who care for patients suffering ...
(Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
(Date:7/28/2014)... July 28, 2014 It’s a hard truth: ... benefits to further their post-secondary education are failing to obtain ... released this year. And according to an analysis by ... is veteran students’ uninformed choice of college majors, which leads ... of the study: Some 51.7 percent of post-9/11 veterans using ...
(Date:7/28/2014)... 28, 2014 Research and Markets has ... Market 2014-2018" report to their offering. ... is a technique used to determine the size of a ... is crucial to analyze the size of particles as it ... analysis is performed to determine the behavior and nature of ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2
... 2012 Oxford BioTherapeutics (OBT) today announces that ... advisor and non-executive director.  Dr Begley, who was the Vice ... Amgen, will take on a key role in helping shape ... its pipeline of oncology antibody-based drugs into clinical development. ...
... Advanstar Communications, is pleased to announce the agenda for ... held April 26 - 27, 2012 at the Loews ... share their strategies for improving patient outcomes and product ... Conference highlights include: , The ...
... Jan. 11, 2012  goBalto, developer of new generation ... completed a FDA 21 CFR Part 11 compliance ... trials application. Tracker,s successful audit will help both ... running clinical trials comply with FDA rules and ...
Cached Biology Technology:Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 2Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director 3Complete Agenda Announced for 11th Annual Patient Adherence Forum 2goBalto Completes a Successful FDA 21 CFR Part 11 Compliance Audit 2
(Date:7/28/2014)... Norwegian explorer Roald Amundsen reached the South Pole in ... arrived long before any human. , Using data from ... the Antarctic continent, including the South Pole, a group ... (DRI) in Reno, Nevada, created the most accurate and ... southernmost continent. The new record, described in an article ...
(Date:7/28/2014)... Yale School of Medicine have pinpointed a mechanism in part ... in the blood, linking it to both type 1 and ... 28 issue of Proceedings of the National Academies of ... enzyme located in a part of the hypothalamus known ... in motion that control glucose levels in the blood," said ...
(Date:7/28/2014)... findings of a new study suggest two ways to effectively ... as well in obese women, compared to women of a ... one-size-fits-all method, researchers say, but as the population has increased ... works for obese women. Studies have consistently found that obesity ... which may in turn affect how well the pill prevents ...
Breaking Biology News(10 mins):Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3Glucose 'control switch' in the brain key to both types of diabetes 2Strategies identified to improve oral contraceptive success with obese women 2
... developed a clever method to purify parasitic organisms from ... proteomic studies and a deeper insight into the biology ... each year. Many infectious pathogens, like those ... have a complex life cycle alternating between free-living creature ...
... carbon dioxide from burning of fossil fuels might be kept below ... next few decades, say researchers. They say that less plentiful oil ... greater supplies of coal mean that it must be the main ... Biogeochemical Cycles . , ...
... addition to social factors when selecting a mate. In ... PLoS Genetics, scientists in China, France, and the ... be involved in mate choice in some human populations. ... Major Histocompatibility Complex (MHC), a large genomic region involved in ...
Cached Biology News:Curbing coal emissions alone might avert climate danger, say researchers 2Curbing coal emissions alone might avert climate danger, say researchers 3
See product name for description....
RAT ANTI MOUSE TCR V BETA 7:RPE Immunogen: T-cell lymphoma TK1...
... Serum • Rhesus serum is collected from ... years of age. Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Porcine Serum US Origin 6 Months or Older...
Biology Products: